Type of information: Series B financing round
Company: Lexeo Therapeutics (USA-NY)
Investors: D1 Capital Partners (USA-NY) Eventide Asset Management (USA-MA) CAM Capital (USA-NY) Verition Fund Management (USA-NY) Laurion Capital Management (USA-NY) Gray’s Creek Capital Partners (USA-CT) Longitude Capital (USA-CA) Omega Funds (USA-MA) Lundbeckfonden Ventures (DK) PBM Capital (USA-VA) Janus Henderson Investors (UK) Invus (USA-NY) Woodline Partners LP (USA-CA Alexandria Venture Investments (USA-CA)
Amount: $100 Million
Funding type: series B financing round
Planned used: Proceeds from the financing will support the development of Lexeo’s expanded pipeline, including recently acquired cardiac gene therapy programs and additional preclinical programs focused on the genetic causes of Alzheimer’s disease (LX1020 and LX1021).
The financing will also advance the company’s three lead investigational AAV-mediated gene therapy programs
through clinical development to meaningful value inflection points: -LX2006, an IV-administered gene therapy for cardiomyopathy associated with Friedreich’s ataxia (FA), -LX1004, a central nervous system (CNS)-administered gene therapy for CLN2 Batten disease - LX1001, a CNS- administered gene therapy for APOE4-associated Alzheimer’s disease.
Therapeutic area: Rare diseases - Genetic diseases -Neurodegenerative diseases - Cardiovascular diseases